Paradigm Biopharmaceuticals . Share Price and Company Fundamentals
Last traded: Today at 5:10 AM
Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulphate sodium drugs in the injectable form for the treatment of bone marrow edema lesions, osteoarthritis, mucopolysaccharidosis, and alphaviral arthritis diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.
|Primary activities||Paradigm Biopharmaceuticals is a late-stage drug development company with the mission to develop and commercialise pentosan polysulfate sodium for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, ageing, dege|
|Industry / Sector||Biotechnology / Healthcare|
|Mailing address||500 Collins Street Level 15 Melbourne VIC 3000 Australia|
|Phone / Fax||/|
|Share registry||COMPUTERSHARE INVESTOR SERVICES PTY LIMITED|
Paradigm Biopharmaceuticals . does not pay dividends.
As of Jan 2022, following are the company executives and directors listed on Paradigm Biopharmaceuticals ..
|Dr. Donna L. Skerrett M.D., MS||Interim CEO & MD, Chief Medical Officer and Exec. Director||64||1.12M|
|Mr. Justin Cahill||Chief Financial Officer|
|Dr. Ravi Krishnan||Chief Scientific Officer|
|Ms. Simon White||Director of Investor Relations|
|Dr. Michael Imperiale||Global Head of Drug Safety & MPS|
|Ms. Beverley Huttmann||Commercial Head|
|Ms. Michelle Coffey||Global Head of Regulatory Affairs|
|Dr. Mukesh Ahuja||Global Clinical Head of OA|
|Mr. Kevin G. Hollingsworth CGMA, FCMA, FCPA||Company Sec.||68|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Paradigm Biopharmaceuticals . is and its enterprise value is .
The PAR's stocks Beta value is 1.36 making it 36% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Paradigm Biopharmaceuticals . (PAR)
Paradigm Biopharmaceuticals . (ASX:PAR) Frequently Asked Questions
1. What is Paradigm Biopharmaceuticals .'s Stock Symbol?
Paradigm Biopharmaceuticals . trades on ASX under the ticker symbol "PAR".
2. What is Paradigm Biopharmaceuticals .'s stock price today?
One share of PAR stock can currently be purchased for approximately $1.565.
3. How can I contact Paradigm Biopharmaceuticals .?
Paradigm Biopharmaceuticals .'s mailing address is 500 Collins Street Level 15 Melbourne VIC 3000 Australia. The company can be reached via phone at .
4. What is Paradigm Biopharmaceuticals .'s official website?
The official website of Paradigm Biopharmaceuticals . is https://www.paradigmbiopharma.com.
5. Which share registry manages Paradigm Biopharmaceuticals .'s stock?
Paradigm Biopharmaceuticals .'s stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.